INTRODUCTION
A variety of inherited ataxias are known, and in several of these specific biochemical abnormalities have been found (1) (2) (3) (4) (5) (6) . Recently, we have demonstrated an inReceived for publication 21 March 1969 and in revised form 5 November 1969. herited defect in the oxidative decarboxylation of pyruvic acid in a boy with an intermittent ataxic syndrome (7, 8) . The patient appears to resemble a child studied by Lonsdale and associates (9) (10) (11) . Details of the studies in our patient which revealed a hereditary defect in pyruvate decarboxylase (2-oxo-acid carboxy-lyase. E.C. 4.1.1.1.) are presented below.
METHODS

Clinical studies
The patient, an 8 yr old boy, has had documented episodes of ataxia two to six times a year since he was 16 months old. Most attacks have followed nonspecific febrile illnesses or other stresses. Symptoms have lasted a few hours to over a week, and in severe attacks he has been bedridden. Extensive evaluations at several medical centers have revealed a cerebellar and choreoathetoid movement disorder during attacks but only generalized "clumsiness" at other times.
There was no family history of ataxia, no evidence of consanguinity, and no history of anoxia or significant head injury. Pregnancy and delivery were unremarkable.
On admission, the patient had definite cerebellar ataxia. mild but definite choreoathetosis, irregular "wandering" eye movements without true nystagmus,1 and minimal dystonic posturing. His symptoms cleared, and after 4 days only mild cerebellar signs remained.
The concentration of pyruvic acid in the patient's blood was about three times the normal level, whereas the concentration of alanine was about twice normal, and that of lactic acid slightly increased (Table I ). The urinary alanine content was elevated; analyses by paper chromatography have shown a similar elevation.2 No other abnormality in plasma or urinary amino acids was noted. The blood pyruvic acid levels in the father were usually within the normal range although occasional values were elevated. The single slightly elevated value for the mother was from blood obtaimed in clinic and may not represent a truly basal level. The pyruvic acid concentration in the brother's blood, and (14) . Results with normal subjects agreed with those of previous workers, and values for the normal rangse are derived from those quoted by several authors (15) (16) (17) .
Further details of the clinical history and examinations and of other laboratory studies, including muscle biopsy, will be reported elsewhere. ' 
Metabolic studies
Methods and materials. L-Glutamic acid-U-`4C (218 mCi/ mmole) and L-alanine-U-J4C (125 mCi/mmole) from New England Nuclear Corporation were repurified by paper chromatography. Sodium pyruvate-1-"C from New England Nuclear (2.89 and 3.27 mCi/mmole) and from AmershamSearle (23.8 mCi/mmole) and sodium pyruvate-2-14C from Tracerlab (3.16 mCi/mmole) were stored at -20'C in a vacuum dessicator and used without further purification. Sodium acetate-1-14C from New England Nuclear (31.0 mCi/mmole) and sodium bicarbonate-j'C from AmershamSearle (44.4 mCi/mmole) were also used without further purification. The palmitic acid-1-4C (55.2 mCi/mmole) from Amersham-Searle was at least 98%o radiopure by gasliquid chromatography.
Thiamine hydrochloride was obtained from Nutritional Biochemicals Corp., DL-carnitine (A-grade) from Calbiochem, crystallized human serum albumin from Pentex Corp., bovine serum albumin (fraction V) from Armour Pharmaceutical Co., methylcellulose (15 NaCl (18) and left in an ice bath for 45 min. The supernatant fluid was removed with a glass pipette, centrifuged (600 g for 10 min at 4°C), and the cell pellet suspended in 1 ml of 0.11 M NaCl, 0.04 M phosphate buffer (pH 7.4). Water (3 ml) was added to lyse contaminating red cells; exactly 90 sec later 1 ml of 3.6% NaCl was rapidly pipetted into the solution (18) . The cells were washed three times more by centrifugation and resuspension in about 30 ml of buffered saline each time. The final pink pellet was suspended in buffered saline, and the cells in a sample counted in a Coulter Counter. Cells were incubated at 37°C in 20-ml polyethylene vials, usually for 1 hr. Each vial contained 1.5-5.0 X 10' cells in 3 ml of buffered saline, and either radioactive pyruvic acid (0.16 ,umoles), glutamic acid (0.0029 /Lmoles), sodium acetate (0.016 ,umoles), or alanine (0.0015 /Amoles). Vials were closed with serum caps from which were suspended disposable plastic center wells (Kontes Glass Corp.) containing filter paper wicks. After incubations with pyruvate and glutamate, 0.2 ml of 1 M hyamine hydroxide in methanol was added to each well and 0.4 ml of 50% H2SO4 to each vial; vials were shaken for 1 hr more, the wells transferred to counting vials containing 15 ml of 0.6% PPO in toluene, and radioactivity measured in a Packard model PR-1 scintillation counter. With acetate as substrate, acidification was avoided to prevent collection of volatile substrate with the 14C02; each plastic well then contained 0.18 ml of 8%o NaOH throughout the incubation, and samples were counted in 0.4% PPO, 0.05%o POPOP in toluene-methanol 2: 1. To measure incorporation of radioactive amino acids into protein, the incubated cell suspension was added to an equal volume of 10% trichloroacetic acid; the vial was rinsed with 0.5 ml of 1% bovine serum albumin solution and then with a few drops of water, and the washings were added to the trichloroacetic acid. Proteins were prepared by the method of Siekevitz (19) , heated in counting vials for 20 min at 60°-70°C with 1 ml of 1 M hyamine hydroxide in methanol, and counted after cooling and addition of 15 ml of 0.6%o PPO in toluene. Duplicate control vials containing boiled cells or no cells were incubated simultaneously with active preparations and results corrected accordingly.
Fibroblast incubations. Fibroblasts derived from skin punch biopsies were cultured by previously described techniques (20) in Eagle's minimal essential medium, modified to contain 0.16% NaHCOs, nonessential amino acids, neomycin (50 ,ug/ml), and 0.01%o Phenol Red (21, 22) Co., Stamford, Conn.). Sonication at 2 A current was in six bursts of 5 sec each separated by 10-to 15-sec cooling periods. No cells were seen in these preparations under phase microscopy, and activity was similar whether preparations were used as such or only after a centrifugation which would have removed unruptured cells.
Pyruvate decarboxylase activity was measured by a modification of the method of Reed and Willms (24) . Incubations were in duplicate for 30 min at 30°C. Each test tube contained, in a volume of 0.14 ml, The low rate of oxidation of pyruvic acid-1-J4C by the patient's fibroblasts was clearly demonstrated when carnitine was added to prevent accumulation of acetyl coenzyme A (26) and '4CO2 was collected without acidification (Table IV) . Oxidation by the father's (Fig. 4) , oxidation by the patient's cells was again low, and by his parent's cells was just below the normal range.
Cell-free preparations. Pyruvate decarboxylase activity was proportional to the amount of fibroblast protein added, under the experimental conditions used (Fig.   5 ). Ferricyanide was used as an electron acceptor to avoid measurement of the later oxidative steps in the pyruvate dehydrogenase complex (24) . The concentration of pyruvic acid, 0.2 mmoles/liter, was about twice that in normal blood under basal conditions (12) .
Pyruvate decarboxlase activity in sonicated fibroblasts from the patient was less than 20% of that in preparations from controls ( Table V) . The value for the father was again intermediate between that of the patient and those of controls, and the value for the mother coincided with the lowest control value. The activity of this enzyme was also low in homogenized muscle from the patient ( See text for details.
Excess thiamine pyrophosphate was routinely added to the cell-free preparations in which the defect was demonstrated. In preparations from both the patient and controls, the absence of added coenzyme was associated with 20-30% lower activity, whereas the addition of twice the usual amount of coenzyme caused no significant change (Table VI) . Complete dissocation of pyruvate decarboxylase apoenzyme from the coenzyme has been shown usually to require alkaline conditions (27, 28) . Michaelis-Menton constants (Km) were derived from the curves shown in Fig. 6 by the method of double reciprocals (29) .
arranged into several groups on the basis of small differences and might be consistent with the possible existence of different forms of the enzyme (Table  VIII) . (35) , but would perhaps not be surprising in view of the apparent widespread ccurrence of genetic polymorphism (36) (37) (38) (39) . Further studies of pyruvate decarboxylases in human and other tissues may clarify some of these problems.
DISCUSSION
The clinical manifestations in the patient may be related to the defect in pyruvate decarboxylase. Elevation of pyruvic acid concentration was the most marked abnormality in the patient's blood. The accumulation of alanine and lactic acid could be secondary to hyperpyruvicemia. The genetic defect in the patient may involve brain as well as fibroblasts, white cells, and muscles. In rats, where cerebral tissues were available for study, the Km values for pyruvate decarboxylase were similar for brain, 2.1 4-0.2 X 10-' mole/liter, and for muscle, 4.5 ±2.5 X 10-' mole/liter (mean +SE, four determinations in each tissue). Reduction in cerebral pyruvate decarboxylase is associated with a movement disorder in thiamine-deficient rats (40) , and in patients pyruvic acid levels frequently rise during fever, perhaps because of relative thiamine deficiency (41) (42) (43) . Fever might be expected to precipitate a movement disorder in a patient whose capacity to decarboxylate pyruvic acid was already low.
The combination of clinical and biochemical findings in the patient described above distinguish him from other patients with chronic hyperpyruvicemia or intermittent ataxia. The combination of characteristics is distinct from those described in lactic acidosis (44) (45) (46) (47) (48) (49) (50) , thiamine deficiency (51-55), pyruvate carboxylase deficiency (5, 56) , the subacute sclerosing leukoencephalopathy of Leigh (5, (57) (58) (59) (60) (61) , or in the Friedreich-like syndrome described by Dunn, Perry, and Dolman (10, 62) . Lonsdale and associates (9-11) have recently studied a mentally slow child with hyperpyruvicemia and persistent hyperalanuria and hyperpyruvicemia; the enzymatic defect in this patient has not been described. Intermittent ataxia has been reported in both sporadic (63) and familial (64, 65) distributions, and has been associated with inherited abnormalities in amino acid metabolism in Hartnup disease (2) and in late onset branched-chain aciduria (6, 66) . Intermittent ataxia with hyperpyruvicemia, with hereditary pyruvate decarboxylase deficiency, may constitute still another biochemically defined type of ataxia.
